Floatz logo

CEPHALOTAXINE 4-METHYL (2R)-2-HYDROXY-2-(4-HYDROXY-4-METHYLPENTYL)BUTANEDIOATE (ESTER)

Leukemia

M.D. Anderson Cancer CenterSmall moleculePhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
65/ 100

Competitive context

124 Active assets in the Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BB
Daunorubicin
Richard Stone, MD
Phase 3BB
PEGASPARGASE
Dana-Farber Cancer Institute
Phase 3BB
THIOGUANINE ANHYDROUS
Incyte Corporation
Phase 3BB

View all 50 →

Same molecule, other indications

CEPHALOTAXINE 4-METHYL (2R)-2-HYDROXY-2-(4-HYDROXY-4-METHYLPENTYL)BUTANEDIOATE (ESTER) is also rated in:

acute myeloid leukemiaActive
B
Indicative · Phase 3
59 / 100
View asset →
childhood acute lymphoblastic leukemiaActive
B
Indicative · Phase 2/3
57 / 100
View asset →
acute myeloid leukemia, FLT3 internal tandem duplicationDormant
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →